

Vermont New Product Launch Report

| NDC | DRUG PROD DESC | INTRODUCED TO MARKET DATE | WAC AT INTRODUCTION |
|---|---|-----------------------------------|------------------------------|
| 74527-0022-02 | MARGENZA™ (margetuximab-cmkb) 25mg/mL per Vial, 1 Vial per Pack | 3/4/2021 | \$2077.00 |
| MARKETING PRICING PLAN | | MARKETING PRICING NONPUBLIC | |
| | | Y | |
| | | | |
| | | | |
| | | | |
| ESTIMATED PATIENTS | | BREAKTHROUGH THERAPY INDICATOR | PRIORITY REVIEW INDICATOR |
| Confidential Trade Secret Information of MacroGenics, not for public disclosure | | N | N |
| | | | |
| ACQUISITION DATE | | ACQUISITION PRICE NONPUBLIC | ACQUISITION PRICE COMMENT |
| GENERAL COMMENTS | | | |
| | | | |
| None. | | | |



Vermont New Product Launch Report